Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shukra PharmaceuticalsBOM:524632 -2.83%73 Days Inventory is 213.57 as of Mar. 2026, which is 113% above its 10-year median of 100.10. GuruFocus rates BOM:524632 with a GF Score™ of 73/100 and a GF Value™ of ₹8.62 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Shukra Pharmaceuticals ranks worse than 84.62% on this metric.
The historical rank and industry rank for Shukra Pharmaceuticals's Days Inventory or its related term are showing as below:
BOM:524632'
s Days Inventory Range Over the Past 10 Years
Min: 22.44 Med: 100.1 Max: 305.16
Current: 305.16
During the past 13 years, Shukra Pharmaceuticals's highest Days Inventory was 305.16. The lowest was 22.44. And the median was 100.10.
BOM:524632's Days Inventory is ranked worse than 84.62% of 923
companies
in the Drug Manufacturers industry
Industry Median: 164.87
vs BOM:524632: 305.16
Shukra Pharmaceuticals's Days Inventory
declined
from Mar. 2025 (515.27) to Mar. 2026 (213.57).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Shukra Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.43.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shukra Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 2.20.
Shukra Pharmaceuticals (BOM:524632) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Shukra Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Shukra Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Shukra Pharmaceuticals Days Inventory Related Terms
Shukra Pharmaceuticals Days Inventory Historical Data
* Premium members only.
The historical data trend for Shukra Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shukra Pharmaceuticals Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Shukra Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shukra Pharmaceuticals (BOM:524632) has a Days Inventory of 213.57 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shukra Pharmaceuticals and its competitors. This is 113% above median its historical median of 100.10. Over the past decade, Shukra Pharmaceuticals' Days Inventory has ranged from 22.44 to 305.16. According to the industry distribution chart, Shukra Pharmaceuticals ranks #781 out of 923 companies in the Drug Manufacturers industry, placing it in the top 84.6%.
Is Shukra Pharmaceuticals' Days Inventory too high?
Shukra Pharmaceuticals' current Days Inventory of 213.57 is 113% above median its 10-year median of 100.10. Over the past 10 years, this metric has ranged from a low of 22.44 to a high of 305.16. The Drug Manufacturers industry median Days Inventory is 164.87. Shukra Pharmaceuticals' value of 213.57 is 29.5% above this industry median. Based on the distribution chart, Shukra Pharmaceuticals ranks #781 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Shukra Pharmaceuticals has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Days Inventory compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shukra Pharmaceuticals ranks #781 out of 923 companies for Days Inventory. This places Shukra Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 164.87. Shukra Pharmaceuticals' value of 213.57 is 29.5% above this benchmark. Historically, Shukra Pharmaceuticals' own Days Inventory has ranged from 22.44 to 305.16 over the past decade. While the company's 10-year median is 100.10 vs. the industry median of 164.87, Shukra Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.87, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shukra Pharmaceuticals's current Days Inventory of 213.57 is 29.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Shukra Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shukra Pharmaceuticals's current Days Inventory is 213.57, which is 113% above median its own 10-year median of 100.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.62, compared to a current price of ₹30.18 — trading 250.1% above its estimated fair value. The current Days Inventory is 213.57, which is 113% above median its 10-year median of 100.10 and 29.5% above the Drug Manufacturers industry median of 164.87. Shukra Pharmaceuticals' overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Days Inventory is 213.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹30.18 is trading 250.1% above its estimated GF Value™ of ₹8.62.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Days Inventory: 213.57 (113% above median its 10-year median of 100.10)
GF Value™: ₹8.62 vs. price of ₹30.18 (250.1% above fair value)
Industry Position: 29.5% above the Drug Manufacturers median (#781 of 923)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
73GF Score
Get the complete analysis for BOM:524632
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
